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Sclerosis
Gulfaraz Khan and Asma Hassani
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system in which the body’s immune system is abnormally directed towards the 
myelin sheaths covering the nerve fibers. What triggers the neuroinflammation 
and autoimmune destruction of the myelin sheaths remains unknown. However, 
it is widely accepted that susceptibility depends on a combination of genetic and 
environmental factors and their interactions. With little chance of influencing 
genetic predisposition, the importance of identifying risk factors which could be 
modulated to either prevent the on-set of MS or to ameliorate the course of the 
disease, is an attractive alternative. An accumulating body of evidence, including 
our own recent study involving over 1000 MS and non-MS samples, indicates that 
Epstein-Barr virus (EBV), a common herpesvirus, could be involved. In this chap-
ter, we review the studies linking EBV to MS and propose an explanation by which 
this common virus could be involved in the pathogenesis of MS.
Keywords: multiple sclerosis, autoimmunity, neuroinflammation, Epstein-Barr 
virus, seroepidemiological evidence, postmortem studies
1. Introduction
Multiple sclerosis (MS) is a progressive disease in which multiple regions in the 
brain, spinal cord and optic nerve undergo myelin destruction or demyelination. It 
is believed that an aberrant immune response mistakenly attacks the myelin sheaths 
in the central nervous system (CNS) resulting in the formation of focal demyelin-
ated plaques; the hallmark of MS [1]. In spite of extensive search, the identity of 
the factor(s) that triggers the immune assault against the myelin remains elusive. 
It is generally accepted that MS is a complex disease and most likely involves both 
genetic and environmental factors [2]. Although no single gene has been identi-
fied to be responsible in the development of MS, certain HLA haplotypes, such as 
HLA-DRB1 have been shown be associated with MS susceptibility [3]. Furthermore, 
the fact that MS is more prevalent in certain races such as Caucasians [4, 5] and 
incidence rates are increasing in some ethnic groups such as blacks [6, 7] supports 
the involvement of genes in the development of MS. Although the risk of MS is 
significantly higher in individuals with first-degree relatives with MS, this still does 
not explain the occurrence of MS in majority of cases. In fact, MS concordance in 
monozygotic twins is only around 25% [8, 9]. This clearly indicates that environ-
mental factors play a key role in the development of MS in genetically predisposed 
individuals.
Multiple Sclerosis
2
1.1 Environmental risk factors for MS
In support of the above observations, MS prevalence has been reported to be higher 
in the northern hemisphere, but lower towards the equator. However, recent studies 
indicate that this pattern of distribution, known as the latitudinal gradient, is chang-
ing in some countries such as Norway and USA [10–12]. Moreover, migration studies 
indicate that the increasing burden of MS is due to exposure to certain factors in the 
environment, which may account for a bigger proportion of MS risk than genetic 
factors. These studies show that leaving countries with high MS incidence prior to 
reaching adolescence, to regions with low MS incidence, confers protection against 
developing the disease [13]. Similarly, migrating in the opposite direction is linked to 
increased risk of developing MS [14–16]. These protective and MS predisposing effects 
have been shown to occur in a single generation, and this is highly unlikely to be due to 
effects of genes which usually manifest on longer periods of time [17].
Additionally, exposure to specific environmental agents at a young age seems to 
be critical in shaping the risk of developing MS [18]. The past few decades have seen 
a rapid accumulation of epidemiological data pointing to a number of different envi-
ronmental factors that could potentially be involved in MS pathogenesis. However, no 
single causative agent has yet been unequivocally shown to be central to MS develop-
ment [19]. Environmental risk factors associated with MS include sunlight exposure 
and serum levels of vitamin D, smoking, obesity, female sex hormones, and infection 
with Epstein-Barr virus (EBV) [20–22]. Among these factors, infection with EBV, 
particularly when manifested as infectious mononucleosis (IM), appears to have the 
most significant and consistent association with the risk of developing MS [23].
1.2 Infectious risk factors for MS: Hygiene hypothesis
The notion that an infectious agent is involved in the pathogenesis of MS is not 
new. A number of observations, including MS outbreak in the Faroes islands during 
World War II, which coincided with the British occupation of the islands [24], and 
MS occurrence in clustering fashion (e.g. familial clustering of MS), suggested 
an infectious cause for MS [17]. The hygiene hypothesis was used to provide an 
explanation for such involvement [21], assuming that certain infections occurring 
during the first few years of life can protect against MS, whereas exposure to the 
same infections later in life, predisposes to MS [25]. The hygiene hypothesis also 
partly explained the geographical distribution of MS, in that it is less common in 
tropical regions that are known to be endemic to certain microbial infections. In 
these areas, children tend to acquire infections very early in life [26, 27]. Similarly, 
MS incidence seems to rise in tropical regions [28] that have witnessed improved 
feasibility of vaccines and antibiotics and enhanced sanitary conditions which have 
led to decreased childhood infections [29–31]. However, some epidemiological 
observations such as the finding that the risk of MS in individuals who have never 
been exposed to EBV is 10 fold lower than in those who were exposed to childhood 
EBV infection [32], cannot be explained by the hygiene hypothesis.
2. Epstein-Barr virus (EBV)
EBV is a common human herpesvirus, infecting over 90% of the population 
worldwide [33]. Generally, EBV infection is considered to be one of the early asymp-
tomatic childhood infections and in the vast majority of the infected individuals, 
the virus persists for life without causing disease. Bizarrely, if primary infection is 
delayed until adolescence, as commonly noted in developed countries, the virus can 
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cause an acute self-limiting symptomatic infection known as infectious mononucleo-
sis (IM) [34]. Importantly, EBV has oncogenic properties and in a very small per-
centage of individuals, the virus can induce life-threatening lymphoid and epithelial 
malignancies, accounting for approximately 150,000 deaths annually [35, 36].
EBV is transmitted from person to person through salivary exchange. However, the 
details of the early steps in EBV infection remain unclear. Two models have been pro-
posed. In the first model, it is suggested that EBV initially infects tonsillar epithelial 
cells where it undergoes lytic replication with subsequent infection of B-lymphocytes. 
In the second model, it is suggested that EBV directly infects B-lymphocytes with-
out the involvement of epithelial cells [37, 38]. Whatever the initial cellular target, 
one thing is fairly well-established; the cellular site of long-term EBV persistence is 
B-lymphocytes [39, 40]. These cells can be transformed and immortalized by EBV 
when grown in in vitro cultures, forming what are known as lymphoblastoid cell lines 
(LCLs). In LCLs, a number of viral latent products, namely 2 EBV encoded RNAs 
(EBER 1 and 2), 6 EBV nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and LP) and 3 EBV 
latent membrane proteins (LMPs 1, 2A and 2B) are expressed [33]. The expression 
of these latent products in infected cells is referred to as EBV latency III program and 
is typically observed in EBV associated post-transplant lymphomas [41] and in IM 
[42]. When EBERs, EBNA-1, LMP1 and LMP2 are expressed, it is known as latency 
II, typically seen in EBV associated Hodgkin’s lymphoma. In latency I, only EBERs 
and EBNA-1 are expressed, as seen in Burkitt’s lymphoma. In latently infected asymp-
tomatic EBV carriers (>90% of the population), infected B cells express EBERs only 
[43]. Since no viral proteins are expressed in these cells, the virus can remain out of 
the radar of the host immune system. This strategy allows the virus to be dormant, but 
still dangerous. Moreover, the virus utilizes an array of viral encoded miRNAs to target 
immune associated mRNAs, aiding its escape from host defenses [44, 45]. Thus, EBV 
has evolved to be a master manipulator of the immune system, ensuring its persistence 
for the life of its host, even in the face of a competent immune system.
Beside the latent infection described above, a lytic infection can occasionally 
occur resulting in production of new virions. The expression of the immediate early 
lytic protein BZLF1 signals the beginning of the lytic cycle. Whether it is latent or 
lytic infection, an efficiently functioning immune system is essential to keep EBV 
infection under control and maintain a homeostatic virus-host relationship [46]. 
Thus, any disruption of the intricate connection between EBV and the immune 
system can lead to serious health conditions, for instance EBV-induced malignan-
cies and some autoimmune disorders such as MS. Based on an accumulating body 
of evidence from epidemiological, serological and postmortem studies, it is now 
widely believed that EBV is associated, directly or indirectly in the pathogenesis 
of MS [20–22]. However, the details of how EBV induces or promotes an aberrant 
immune response against myelin self-antigens in MS remain unknown.
3. Epidemiological link between EBV and MS
A considerable amount of literature has been published on the link between the 
epidemiology of MS and EBV infection. Early reports consistently showed higher 
prevalence of EBV infection in MS patients compared to the general population [47, 
48]. This difference was particularly pronounced in the pediatric cohort, where 
almost 100% of children with MS were EBV seropositive compared to 72% matched 
controls [49–52]. Consistent with these findings, MS risk was found to diminish in 
individuals who have never been exposed to EBV infection (the odds ratio of devel-
oping MS is 0.06 in a seronegative person compared to 13.5 in an EBV seropositive 
person). Furthermore, continuing to be EBV seronegative keeps MS risk to about 
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10-fold lower than those who seroconvert [53] and about 20-fold less than those with 
a history of IM, the primary symptomatic EBV infection [32]. These reports suggest 
that the risk of MS rises in EBV-seronegative individuals soon after they seroconvert 
as confirmed by a nested case–control study on 305 MS cases and 610 controls [54].
Interestingly, IM has a strikingly similar distribution to that of MS [55]. Moreover, 
females report IM symptoms earlier (more prolonged), more frequently, and with 
more severity than their male counterparts. Females also tend to have higher anti-EBV 
titers and are believed to mount stronger response against EBV [56, 57]. In demon-
stration of the correlation between IM and the risk of MS, a case–control study found 
that history of IM increases the risk of developing a CNS demyelinating disease, 
particularly in genetically susceptible individuals who are HLA-DRB1*1501 positive 
[58]. In support of these results, a meta-analysis of 14 case–control and longitudinal 
studies reported that history of IM significantly increased the risk of MS by over 2 
folds [59]. Furthermore, this increased risk persists for at least 30 years post EBV 
infection [60], suggesting that symptomatic EBV infection manifested as IM may be a 
prerequisite to developing the autoimmune response associated with MS [61].
4. Serological link between EBV and MS
More evidence has been brought to light by serological studies investigating 
antibody response against EBV antigens in MS patients compared to that in controls. 
One of the most consist piece of evidence is the finding of elevated antibody titers 
against EBNA-1 antigen in the blood, both pre- and post-onset of the disease [62–65]. 
Indeed, individuals with clinically isolated syndromes (CIS) are more likely to develop 
definite MS when they experience elevated antibody response to EBNA-1 [66, 67]. 
Furthermore, serum levels of anti-EBV capsid antigen (VCA) together with anti-
EBNA-1 IgG antibodies seem to also correlate with the risk of MS [68]. In an attempt 
to understand how the humoral response towards EBNA-1 impacts the risk of devel-
oping MS, it was shown that the levels of circulating IgG against certain EBNA-1 epit-
opes, particularly those derived from EBNA-1: 385–420 domain, interact with MS risk 
gene, the HLA genotype DRB1*15 in amplifying MS risk [69]. These findings point to 
similarities between how HLA molecules influence response to EBV antigens and how 
they are involved in inducing autoimmune response [70]. Additionally, the humoral 
response to EBV antigens, specifically anti-EBNA-1 IgG vary between different forms 
of MS, namely CIS, relapsing–remitting and progressive MS [71], suggesting that 
the level of these antibodies is not only predictive of MS onset, but also of disease 
progression. However, it remains debatable whether the humoral level can correlate 
with markers of disease progression such as volumes of T2 MRI lesions, reflective of 
demyelinative disease activity and scores of Expanded Disability Status Scale (EDSS), 
reflective of the progression of physical disability [71–76]. Despite some of these 
inconsistencies in the serological link between EBV infection and MS, studies agree 
on the fact that serum antibody titers to EBNA-1 increase prior to developing MS, and 
hence predictive of MS. In other words, it seems that EBV acts early in provoking an 
immune (humoral) response towards promoting the onset of MS [77]. However, it 
is safe to argue that EBV may be a cofactor contributing with other factors, such as 
genetic susceptibility and vitamin D levels, to the pathogenesis of MS [78, 79].
5. Cellular immune response to EBV in MS
Forty years ago, it was shown that peripheral blood mononuclear cells (PBMCs) 
taken from patients with active MS, spontaneously transformed into LCLs in in vitro 
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culture more readily than PBMCs taken from healthy controls or patients with 
inactive MS [80]. These spontaneously immortalized LCLs were of B-cell origin and 
expressed EBV antigens, including VCA and EBNAs [80]. So, why do PBMCs from 
active MS patients transform more readily compared to those from healthy controls? 
One possible explanation is that the immune response to EBV in MS patients is less 
effective compared to healthy EBV seropositive individuals. Indeed, data from a 
number of different studies indicates that the T-cell response to EBV is aberrantly 
regulated in MS patients and it varies at different stages of the disease [81–83]. CD8+ 
T cells in the blood of MS patients with inactive disease, have been shown to express 
the immune inhibitory molecule, programmed death 1 (PD-1), making these cells 
less efficient in eliminating EBV infected cells [84]. This CD8+ T cell exhaustion is 
believed to be a common feature in many chronic viral infections [85–87], and could 
explain the conflicting results in EBV viral load detected in MS patients. Thus, the 
stage of the disease and the level of T cell exhaustion could account for the higher 
viral load reported in some studies [88, 89], whilst others showed no statistical dif-
ference between MS and controls [89–91]. Further support for an aberrant anti-viral 
immune response in MS comes from the observations that MS patients appear to be 
at increased risk of acquiring certain viral infections such as influenza [92, 93].
A more recent study investigated B cell transformation of PBMCs taken from 21 
MS patients and 21 healthy controls [94]. In order to minimize the effect of T cell 
control of EBV, which may vary from person to person, T cell activity in all PBMCs 
cultures was inhibited using cyclosporine A. Cultures obtained from MS patients 
resulted in significantly higher frequency of B cell transformation compared to 
healthy controls [94]. Whether this was due to MS patients having a higher fre-
quency of circulating EBV infected cells, or due to higher frequency of viral lytic 
replication occurring in MS patients is not clear.
There have also been some attempts to examine differences in the cell-mediated 
immune response against EBV and its antigens in the blood and cerebrospinal fluid 
(CSF) of MS patients [95, 96]. However, these investigations have also yielded 
inconsistent results. Whilst some have reported an increase in frequency of both 
intrathecal EBV reactive CD4+ and CD8+ T cells in MS [96], others have found that 
only CD8+ T cells and not CD4+ T cells are increased compared to controls [95]. 
Moreover, intrathecal CD4+ and CD8+ T cells from MS failed to react to a number 
of common autoantigens suspected to be targets of immune response in MS [97]. 
Thus, the identity of the target antigen for the autoreactive T cells remains elusive. 
A very recent study has reported that intrathecal CD4+ T cells from HLA-DRB3 
positive MS patients reacted with GDP-L-fucose synthase, an enzyme frequently 
expressed in human cells as well as in bacteria commonly present in the gastro-
intestinal track of MS patients [98]. This tantalizing finding warrants further 
investigations to determine if gut bacterial GDP-L-fucose synthase is indeed the 
primary trigger for the activation of autoreactive T-cells that subsequently migrate 
to the brain and lead to demyelination. It is plausible that EBV could also trigger 
autoreactive T-cells by molecularly mimicry [99–101]. In this context, certain 
epitopes of EBNA-1, EBNA-3A and LMP2 have been shown to be targets of CD8+ T 
cell responses and to cross-react with self-antigens associated with MS pathogenesis 
[102–104]. However, current evidence fails to clearly explain how cell-mediated 
immune responses to EBV antigens may lead to MS.
6. Direct demonstration of the presence of EBV in MS brains
Compared to the blood and CSF, access to brain tissues, particularly fresh tissues 
from MS patients has been difficult and limited. In spite of this, a number of studies 
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have examined brain tissues to explore the link between EBV and the pathogenesis of 
MS. Most of these investigations have been conducted on formalin-fixed, paraffin-
embedded post-mortem tissues. Arguably, these studies have generated the strongest 
and most convincing data implicating EBV in the development of MS. Initial attempts 
aimed at directly demonstrating if EBV was present in MS lesions or not, reported 
either negative results or did not see any difference in EBV positivity between MS 
and control tissues [105, 106]. A subsequent study however, reported the presence of 
EBV in 21/22 MS, but not in non-MS inflammatory neurological conditions [107]. The 
virus was localized to B cells and plasma cells, most notably in the meninges and peri-
vascular infiltrates of active lesions. Additionally, infected cells were found to express 
a number of viral antigens, latent and lytic [107], making them a potential target of 
CD8+ T cells and triggering an inflammatory environment in the CNS [82]. Although 
these findings were confirmed by some subsequent studies [108, 109], others reported 
absence of EBV infection in the MS brain [110–112]. It was argued that the discrepan-
cies in the findings would be due to many different variables, including differences in 
the tissue samples examined, variation in tissue preservation and processing, type of 
fixatives and length of fixation, and the sensitivity and specificity of methods used 
for EBV detection [113]. Moreover, owing to the great heterogeneity of the brain, 
the molecular and cellular environment of one region does not necessarily represent 
another adjacent region, even in the same tissue block [113, 114]. Thus, the absence of 
EBV in one region of the brain, cannot be interpreted to mean that the virus is absent 
from all parts of the brain. Keeping some of these variables in mind, we recently 
conducted an extensive study examining the potential involvement of EBV in MS 
pathogenesis [115]. We analyzed over 1000 samples from MS cases and non-MS 
controls using our highly sensitive EBER-in situ hybridization, PCR, and immuno-
histochemistry methodologies [115]. Our findings indicated that EBV was present in 
most (90%) cases of MS and the virus could be detected in multiple tissue samples 
from each case. Surprisingly, we found EBV not only in B-cells, but also in astrocytes 
and some microglial cells. Significantly, the virus was transcriptionally active in these 
cells and expressed EBNA-1, and to a lesser extent the early lytic cycle protein BZLF1. 
Taken together, these findings support a role for EBV in the pathogenesis of MS.
7. Proposed model of EBV involvement in MS pathology
The data demonstrating the presence of EBV directly in the brain of MS cases 
is fairly robust and convincing evidence in support of a role for EBV in the patho-
genesis of MS. However, the presence of the virus in the brain cannot be simply 
interpreted to imply causality. Although it is possible that EBV infection could be 
a consequence of MS pathology, the observation that EBV seronegative individu-
als have an almost zero risk of developing MS is strong and compelling evidence 
supporting a role for EBV in initiating MS. Ironically, although it is believed that 
T-cells orchestrate and lead the pathogenesis of MS, treatment strategies that have 
been shown to be most effective in controlling disease activity, involve depleting 
B-cells [22, 116]. Moreover, depleting memory B-cells, the very cells that harbor 
EBV, appears to be the most effective [117]. How can these apparently contradic-
tory findings be reconciled? We propose that EBV infected memory B-cells act 
as antigen presenting cells (APC), resulting in the activation of helper T-cells, 
which in individuals carrying certain HLA haplotypes, activate autoreactive B and 
T-cells targeting antigens expressed on oligodendrocytes [102, 118]. In this model 
(Figure 1), disturbances in the integrity of the blood brain barrier (BBB) allows 
EBV carrying memory B-cells to cross into the CNS, triggering a cascade of events 
including, attraction of autoreactive B and T-cells, triggering pro-inflammatory 
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cytokines and microglial activation [118–120]. While most of the EBV infected 
B-cells infiltrating into the brain remain latently infected, a small percentage are 
triggered to undergo lytic replication [121, 122, 107], which could explain how CNS 
resident astrocytes and microglial cells get infected [115]. Infection of astrocytes can 
be reconciled by the fact that, like B-cells, they also express CD21, the receptor for 
EBV [123]. Astrocytes are the most abundant cells in the CNS, constituting around 
30% of the total cells. They play an important role in a number of homeostatic and 
neuroinflammatory processes within the CNS, including axon guidance, synaptic 
transmission and controlling BBB [124, 125]. An accumulating body of data now 
indicates that activated astrocytes also play a central role in neurodegenerative 
diseases such as MS [124–126]. Since astrocytes interact with blood vessels to form 
the BBB, any functional impact on these cells could also increase BBB permeability 
and exacerbate infiltration of peripheral immune cells into the CNS [120, 125, 127]. 
This could explain the characteristic perivascular cuffing and presence of inflam-
matory aggregates resembling germinal center (GC)-like structures commonly 
observed in the CNS in viral infections [22, 128]. Although the precise role of these 
tertiary lymphoid aggregates remains unknown, it is likely that they play a key role 
Figure 1. 
Model for EBV involvement in MS pathology. The pathogenesis of MS is no doubt very complex. This is a 
simplified outline of a potential model to explain some of the experimental findings linking EBV to MS. EBV 
persists in memory B-cells in peripheral circulation [39, 40] and in healthy seropositive individuals, they are 
tightly regulated by the immune system. In individuals genetically predisposed to MS, these cells cross the BBB 
and enter the CNS where they trigger an inflammatory response leading to the formation of GC-like structures 
[128, 129]. Most of the infected cells remain latently infected with limited viral gene expression [107, 108]. These 
infected cells could function as APC for the activation of helper T-cells [118] which in individuals carrying 
certain HLA haplotypes [89, 132], leads to the activation of autoreactive B and T-cells that recognize both EBV 
and self-antigens [99, 101, 118]. A small proportion of EBV infected memory B-cells, upon differentiation into 
plasma cells, initiate EBV replicative cycle [121, 122]. The new virions produced, infect other susceptible cells, 
including astrocytes and microglia [115, 123]. Microglia and astrocytes are two main types of cells typically 
providing a protective role against viral infection. In their activated form, they release various pro-inflammatory 
cytokines and immune mediators that activate the immune system to resolve the infection [125, 133]. In MS, 
these chronically activated cells switch from being neuroprotective to neurotoxic [133, 134]. Additionally, 
proinflammatory microglia can also induce activation of astrocytes, which can impact not only the BBB but also 
contribute to neurotoxicity [125, 126]. The combined effects of these multiple events result in MS pathology.
Multiple Sclerosis
8
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
in the immune response to CNS injury [129]. In contrast to previously held views, 
studies now indicate that B-cell differentiation and clonal expansion typically 
known to occur in secondary lymphoid organs, can also occur in the CNS [130]. This 
finding also provides an explanation for the source of oligoclonal immunoglobulin 
bands present in the CSF of most patients with MS. In MS, these GC-like aggregates, 
triggered by EBV infection of the brain, could be responsible for recruiting, activat-
ing and sustaining B and T-cells [119, 118] that inadvertently react to auto-antigens, 
such as myelin basic protein (MBP) and GDP-L-fucose synthase, expressed on 
oligodendrocytes (Figure 1) [98, 99, 101]. Moreover, cellular and viral components 
such miRNAs and EBERs, secreted in exosomes could also promote inflammatory 
and pathological changes that contribute to CNS injury in MS [108, 131].
8. Conclusion
The pathogenesis of MS appears to be a complex process, where both genetic and 
environmental risk factors interplay to promote the development of the disease. The 
evidence implicating EBV as a central player in MS development is substantial. For 
some critics, these pieces of evidence are still not sufficient to charge EBV as the mas-
termind behind the pathogenesis of MS. A very recent study by Pender and colleagues 
goes some way to proving the etiological association [135]. The study demonstrated that 
treating MS patients with autologous EBV-specific T cell therapy can improve symp-
toms and quality of life in most patients [135]. The only absolute and unequivocal proof 
that EBV is central to the development of MS, is to prevent EBV infection in the first 
place by vaccination and then see if the incidence of MS declines. Although a number of 
vaccine candidates have been tested, none have yet been approved for clinical use [136].
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